Skip links

Vas Narasimhan—CEO, Novartis

Vas Narasimhan, the Chief Executive Officer of Novartis is still very important in changing Novartis, which’s one of the biggest pharmaceutical companies in the world. The pharmaceutical industry is dealing with a lot of problems like rules uncertainty about what countries will do and new scientific discoveries happening fast. On 20 January 2026 people, around the world noticed Vas Narasimhans leadership and the direction he is taking Novartis especially when they were talking about how strong the healthcare system is, import taxes and how pharmaceutical companies get their supplies. Vas Narasimhan and Novartis are really making people think about these issues.

Narasimhan has been working hard to change Novartis since he became the CEO. He wants Novartis to be a company that only focuses on creating innovative medicines. Novartis is now putting a lot of effort into finding treatments for big diseases like cancer, heart problems, brain disorders and problems with the immune system.

Under the leadership of Narasimhan Novartis has made things simpler. Gotten rid of businesses that are not important to the company. Novartis is now putting a lot of money into research areas, like gene therapies, special radiation treatments and using artificial intelligence to find new drugs. Novartis is really investing a lot in these areas of research.

A big problem for Novartis in 2026 is the way the company is affected by trade and tariff policies in the United States. The person in charge Narasimhan has said that Novartis is trying to stop being affected by these tariffs by the middle of 2026. Novartis is doing this by making more of its products in the United States and by working with the government. This is what a lot of companies in the industry are doing now. They learned a lesson, from the problems they had with getting products from countries over the past few years. Novartis and other companies want to make their products.

Narasimhan is known for doing more than the basic work. He also really believes in making things that help patients. He says that just because a pharmaceutical company is making money it does not mean they are successful. What really matters is if patients are getting better and if they can get the medicine they need to stay alive. When Narasimhan is in charge Novartis has made sure more people in developing countries can get the medicine they need. At the time Novartis is still making sure the prices of new medicines are fair in countries that are already doing well. Narasimhan and the people, at Novartis are working hard to make sure centric innovation is a big part of what they do.

Narasimhan is making sure that the people who work at the company are responsible for what they do. He wants the company to be really good at science. Narasimhan thinks that the different teams, like the research team, the clinical team and the commercial team should work together closely. He also wants them to make decisions faster. This change in the way the company works has helped to speed up the process of creating drugs. The company is now better, at getting these drugs through the stages of testing. The Narasimhan approach has really helped the companys drug pipeline and the success rates of the drugs in the stages of clinical trials.

As global healthcare systems face rising costs, aging populations, and increasing regulatory scrutiny, Vas Narasimhan’s approach positions Novartis to remain both scientifically competitive and commercially resilient. His focus on innovation-led growth, operational discipline, and strategic risk management continues to define Novartis’s trajectory in 2026, reinforcing its standing as a global leader in modern pharmaceuticals.

Leave a comment